We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
IZERVAY (Astellas Pharma Australia Pty Ltd)
Product name
IZERVAY
Date registered
Evaluation commenced
Decision date
Approval time
218 (255 working days)
Active ingredients
avacincaptad pegol
Registration type
NCE/ NBE
Indication
IZERVAY is indicated for the treatment of adult patients with Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) with an intact fovea and when central vision is threatened by GA lesion growth (see Section 5.1 Pharmacodynamic properties – Clinical Trials).